THE HUMAN ETHER-A-GO-GO RELATED GENE (hERG) encodes the voltage-gated K
ϩ channel ␣-subunit that underlies the rapidly activating delayed-rectifier K ϩ current in the heart (22, 29, 30) . hERG is cotranslationally modified in the endoplasmic reticulum (ER) at N598 by the attachment of N-linked core glycans to generate "immature" glycoprotein and posttranslationally modified to generate the terminally glycosylated "mature" glycoprotein (13, 16, 20, 32) . hERG missense mutations linked to long QT syndrome type 2 (LQT2) typically disrupt hERG transport or trafficking to the Golgi apparatus and plasma membrane, thereby increasing the relative fraction of immature hERG in the ER (1, 31, 33) .
The trafficking of hERG to the Golgi apparatus may depend on the relative stability of "native" and "misfolded" conformations (for review see Ref. 11) . If true, then "traffickingdeficient" LQT2 mutations could disrupt trafficking by decreasing the relative stability of native hERG conformations. Indeed, drugs like the class III anti-arrhythmic E-4031, which bind to hERG with a high affinity, can act as "pharmacological chaperones" that increase trafficking efficiency for traffickingdeficient LQT2 mutations (9, 12, 14, 33) . Unfortunately, most of these drugs block the hERG current (I hERG ), thereby negating any therapeutic potential (for review see Ref. 10) .
Quality control (QC) mechanisms in pre-Golgi compartments (the ER and ER Golgi intermediates) prevent the antegrade trafficking of misfolded proteins and facilitate their degradation in the ER-associated degradation pathway (ERAD) (11) . Identifying QC mechanisms that regulate trafficking-deficient LQT2 mutations may identify novel therapeutic strategies. Studies have suggested that QC compartments in the ER and the ER golgi intermediate compartment (ERGIC) can regulate the trafficking and ERAD of different N-linked glycoproteins (2, 17, 26) . We tested the hypothesis that a distinct pre-Golgi QC compartment negatively regulates trafficking-deficient LQT2 mutations.
MATERIALS AND METHODS
Cell lines and drug exposure. The human embryonic kidney 293 (HEK293) cell lines expressing hERG have been previously described (1, 7, 13, 32) . Cells were cultured at 37°C (5% CO 2) in MEM supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA) and geneticin. For some studies we transiently expressed tsO45-VSV-G protein fused to green fluorescent protein (tsO45-VSV-G-GFP, kindly provided by Dr. Jennifer LippincottSchwartz from the National Institutes of Health) (21) . Cells were transfected with 2 g of tsO45-VSV-G-GFP plasmid DNA using the Amaxa Nucleoflector II (Lonza, Basel, Switzerland). The trafficking of tsO45-VSV-G-GFP is temperature sensitive, and it is retained in the ER in cells cultured at 40°C (nonpermissive temperature). To promote the ER retention of tsO45-VSV-G-GFP, cells were cultured at 40°C overnight before analyses. For pharmacological studies, we added nocodazole (Sigma-Aldrich, St. Louis, MO) dissolved in DMSO to the MEM (final concentration was Ͻ0.1%). Podophyllotoxin, vinblastine, and brefeldin A (bfa) (Sigma-Aldrich) were also dissolved in DMSO (final concentration was Ͻ0.1%) before being added to MEM. Control studies were done in parallel with equivalent amounts of DMSO only.
Electrophysiology. Functional analysis of I hERG was done using standard whole cell patch clamp technique as previously described (7, 8) . The external solution contained (in mM) 137 NaCl, 4 KCl, 1.8
Western blot analysis. Cells for Western blotting were harvested with lysis buffer, and equal masses of total protein were electrophoresed on a 6.5-7.5% SDS-polyacrylamide gel, transferred electrophoretically to nitrocellulose membrane, and probed with anti-hERG (1:500, Santa Cruz Biotechnology, Santa Cruz, CA) and anti-Na ϩ -K ϩ -ATPase (1:1,000, Abcam, Cambridge, MA). We measured the protein concentration using the Bio-Rad DC protein assay. For each experiment protein standards were generated from 2 mg/ml albumin stock by serially diluting BSA stock in 1% Nonidet-P40 buffer. A standard curve of concentration versus absorbance was generated, and we calculated the lysate sample concentrations from the resulting linear regression. Anti-hERG and anti-Na ϩ -K ϩ -ATPase were detected using IRdye 680 goat anti-rabbit (1:20,000, Li-Cor Biosciences, Lincoln, NE) and IRdye 800 donkey anti-Mouse (1:20,000, Li-Cor Biosciences), respectively. The Li-Cor Odyssey infrared imaging system was used for antibody detection and quantification. Representative Western blot data shown are all from the same blot with the same brightness and contrast ratios; however, some lanes were cropped to remove duplicates.
Immunocytochemistry and confocal imaging. Immunocytochemistry and confocal imaging experiments were performed similar to those previously described (8) . HEK293 cells expressing wild-type-hERG (WT-hERG), G601S-hERG, or G601S-hERG and tsO45-VSV-G-GFP were plated in 35-mm petri dishes containing collagen-coated coverslips. Cells were fixed with 4% buffered paraformaldehyde for 10 min, permeabilized with Triton X-100 (0.1%) for 10 min, and rinsed in 0.75% glycine buffer for 10 min to quench background fluorescence. The cells were incubated with 2 ml blocking solution (10% goat serum in PBS) for 1 h to block nonspecific binding sites, and the cells were subsequently incubated with the appropriate primary antibodies: anti-hERG (1:1,000, Alomone laboratories, Jerusalem, Israel), anti-mannose-6-phosphate receptor (1:1,000, M6PR, Abcam, Cambridge, MA), anti-calnexin (1:1,000, Abcam), anti-KDEL (Lys-Asp-Glu-Leu, 1:1,000, Abcam), anti-Sec31a (1:100, BD Labs, Franklin Lakes, NJ), anti-Sec16a (1:100, Bethyl Laboratories, Montgomery, TX), anti-ERGIC-53 (1:1,000, Alexis Biochemicals, Plymouth Meeting, PA), and EEA1 (1:100, Genetex, Irvine, CA) mixed with blocking solution at room temperature. Excess antibody was washed off with three 10-min long rinses of blocking solution. The cells were then incubated with highly cross-absorbed Alexa Fluor 568 goat anti-rabbit IgG (HϩL) antibody (1:500, Invitrogen) and Alexa Fluor 488 goat anti-mouse (HϩL) antibody (1:500, Invitrogen). The cells were washed four times for 10 min with blocking solution alone. After the final wash, the coverslips were mounted onto a slide using ProLong Gold with DAPI mounting medium (Invitrogen). For some experiments with Sec16a and tsO45-VSV-G-GFP, we prepared the cells as described above but instead of using Alexa Fluor 488 goat anti-mouse (HϩL) antibody, we detected immunostaining using the Alexa Fluor 647 goat anti-mouse (HϩL) antibody (1:500, Invitrogen). Imaging was performed at the University of Kentucky Imaging Facility using a Leica TSP SP5 confocal microscope (Leica, Wetzler, Germany). Cells not expressing hERG did not show any immunostaining with anti-hERG (data not shown), and cells did not show any labeling with any of the secondary antibodies when used alone (data not shown). Cells were randomly selected and used for imaging and analysis. Data are shown as representative single z-scan images for each fluorescence signal (fluorescent images). Overlay images of the different fluorescent signals were generated using Autoquant bioimaging software (Media Cybernetics, Bethesda, MD). Overlapping signals of similar intensities colored as red and green are shown as yellow, red, and purple are shown as pink, and green and purple are shown as white. Colocalization analyses were performed using Image J (http://rsbweb.nih.gov/ij/). The Costes' approach was used for correlation analyses between the two fluorescent signals to generate Pearson's coefficient (PC) (3, 6) . The relationship between two fluorescent signals is calculated by linear regression, and the slope provides the rate of association of the fluorescent signals. The PC provides an estimate for the "goodness" of this approximation. The Costes' approach calculates threshold values that minimize the contribution of noise and utilizes statistical analysis based on fluorescent image randomization. The closer the Costes' PC is to 1 the higher the degree of colocalization between the two signals. We found that immunostaining the same primary antibody with both the Alexa Fluor 488 and 566 antibodies generated a mean Costes' PC of 0.83 Ϯ 0.02 (n ϭ 23, data not shown).
Plasmalemma labeling of hERG. Plasmalemma labeling of hERG was done similar to that previously described (8) . Briefly, cells expressing G601S-hERG were plated onto collagen-coated tissue culture plates. The cell culture medium was then supplemented with an anti-hERG antibody that recognizes an extracellular hERG epitope for 1 h (1:250, Alomone Labs). The cells were then washed three times for 10 min in cell culture media without any antibody and then cultured in the secondary IRDye 800 goat anti-rabbit antibody (1: 10,000, Li-cor Biosciences) for 1 h and an Alexa Fluor 680 conjugate of wheat germ agglutinin (WGA) (5 g/ml, Invitrogen). WGA binds to sialic acid and N-acetylglucosaminyl residues and its signal was used as a measure for the total number of cells. Cells were then washed once in PBS for 10 min, and anti-hERG and WGA labeling was measured using the Li-Cor Odyssey infrared imaging system (Li-cor Biosciences). The infrared imaging analysis software quantifies the infrared signal (pixels count) within a predefined area (represented by dashed circles) drawn to exclude nonspecific signals associated with the plastic walls of the individual wells. The relative intensity of the anti-hERG immunolabeling was calculated by normalizing to the corresponding intensity of the WGA labeling. To control for any nonspecific anti-hERG ("background") immunolabeling, experiments were also performed with HEK cells that do not express hERG.
Statistics. Unpaired t-tests were performed on data sets with two groups. For data sets with more than two comparisons, an ANOVA was performed. To identify which experimental groups differed, subsequent unpaired t-tests were performed. P Ͻ 0.05 was considered significant.
RESULTS
We tested the hypothesis that trafficking-deficient LQT2 mutations are regulated by a distinct pre-Golgi QC compartment. Nocodazole, a drug that causes the depolymerization of microtubules, disrupts the organization of pre-Golgi QC com- The fourth column shows a section of the overlay (the white dashed box) in greater detail, and insets show the overlays in greater detail (white dashed box). The scale bars represent 10 m. B: representative whole cell current traces recorded from cells expressing WT-hERG or G601S-hERG in control or noc-treated conditions measured by prepulsing cells to 50 mV for 3 s followed by a test pulse to Ϫ120 mV for 3 s. Mean peak inward current measured during the test pulse from cells in control or noc-treated conditions (*P Ͻ 0.05 compared with control) are shown. C: representative Western blot analyses of cells expressing WT-hERG or G601S-hERG in control or noc-treated (20 M, 18 -22 h, n ϭ 5-6) conditions are shown. Top arrow corresponds to a molecular mass of 198 kDa, the middle arrow corresponds to a molecular mass of 125 kDa, and the bottom arrow corresponds to a molecular mass of 90 kDa. The immunoblots were probed with anti-hERG (red) and anti-Na partments without altering the overall distribution of the ER (2, 17, 26) . We determined the effect that nocodazole treatment has on the subcellular distribution of WT-hERG or the trafficking-deficient LQT2 mutation G601S-hERG expressed in HEK293 cells. Cells were immunostained for hERG and M6PR, an endogenously expressed trans-Golgi protein that was used as a positive control. Scheel et al. (23) show that microtubule depolymerization with nocodazole treatment causes the M6PR immunostaining pattern to go from perinuclear to one that consists of dozens of peripheral puncti. We found that nocodazole treatment differentially affected the intracellular immunostaining for WT-hERG, G601S-hERG, and M6PR (Fig. 1A) . In control conditions, WT-hERG and G601S-hERG showed diffuse immunostaining throughout the cell, and M6PR showed a primarily perinuclear immunostaining pattern. Nocodazole treatment reduced the diffuse intracellular immunostaining of WT-hERG, caused G601S-hERG to redistribute into several, almost discrete, peripheral reticulated membrane compartments (reticula), and fragmented M6PR immunostaining to dozens of puncti throughout the cell. WThERG did not accumulate in the reticula, and the G601S-hERG reticula did not overlap with the M6PR puncti.
Previously, it was shown that long-term nocodazole treatment increases the functional expression of WT-hERG (5). We found that nocdoazole treatment only modestly increased the functional expression of WT-hERG but not G601S-hERG (Fig. 1B) . Additional electrophysiological experiments suggested that the effect of nocodazole on I hERG from cells expressing WT-hERG was not caused by changes in hERG gating (see online supplemental Fig. S1 at the AJP-Cell Physiol website).
Western blot analyses of lysates isolated from cells expressing WT-hERG show both the core and terminally glycosylated hERG protein bands (ϳ135 kDa and ϳ155 kDa, respectively), whereas trafficking-deficient LQT2 channels primarily show only the core glycosylated hERG protein band (1, 31) . We tested whether nocodazole treatment altered the glycosylation of WT-hERG or G601S-hERG. Lysates isolated from cells expressing WT-hERG in control conditions or after nocodazole treatment showed two distinct hERG protein bands that corresponded to core and terminally glycosylated hERG [although nocodazole treatment appeared to slightly reduced the molecular mass of the terminally glycosylated WT-hERG protein band] (Fig. 1C) . Lysates isolated from cells expressing G601S-hERG in control conditions mostly showed only core glycosylated hERG, but lysates isolated from cells expressing G601S-hERG after nocodazole treatment showed a second hERG protein band that corresponded to the molecular mass of terminally glycosylated hERG (Fig. 1C) . Nocodazole treatment did not alter the total amount of hERG protein relative to the Na ϩ -K ϩ -ATPase, the appearance of the heavier G601S-hERG protein band took 6 -12 h to detect using Western blot analyses, and it was observed in cells treated with as little as 0.2 M nocodazole (see supplemental Fig.  S2 ). Nocodazole treatment did not alter the molecular mass of N598Q-hERG, an engineered mutation that prevents N-linked glycosylation of hERG (13, 20) (supplemental Fig.  S2 ), suggesting that the increased molecular mass of G601S-hERG was due to increased terminal glycosylation. Treating cells expressing G601S-hERG with structurally unrelated microtubule depolymerizing agents vinblanstine (10 M) or podophyllotoxin (10 M) also resulted in the appearance of the heavier G601S-hERG protein band (supplemental Fig. S2) .
Together, the data suggest nocodazole treatment increased G601S-hERG terminal glycosylation without affecting functional expression in the plasmalemma. These results are surprising because drugs that act as pharmacological chaperones increase the terminal glycosylation, functional expression, and plasmalemma expression of G601S-hERG (for review see Ref. 10). Indeed, biochemical and electrophysiological studies of cells expressing G601S-hERG after treatment in the pharmacological chaperone E-4031 (10 M for 12 h) showed increased terminal glycosylation (supplemental Fig. S2 ) and the peak negative I hERG measured using the same voltage protocol in Fig. 1B (control ϭ 36 Ϯ 18 pA/pF, n ϭ 7; E-4031 treatment/washout ϭ 108 Ϯ 8 pA/pF, n ϭ 7, P Ͻ 0.05). Immunolabeling cells expressing G601S-hERG using an extracellular anti-hERG antibody showed that treating cells in the E-4031 (but not nocodazole) increased plasmalemma anti-hERG immunolabeling of intact cells (Fig. 2) . The data suggest that nocodazole does not act as a pharmacological chaperone to increase plasmalemma expression of G601S-hERG.
The effect that nocodazole has on the perinuclear targeting of Golgi enzymes is well documented (for review see Ref. 28) . Studies show that incubating cells in nocodazole typically causes trans-Golgi enzymes like M6PR to redistribute into Golgi fragments near ER exit sites in a relatively short amount of time (minutes). Our observation that nocodazole treatment caused G601S-hERG to accumulate into reticula is intriguing because such a discrete phenomenon has not been described. We determined how quickly nocodazole treatment caused G601S-hERG to redistribute into the reticula. Figure 3A shows that, although nocodazole treatment had qualitatively different effects on G601S-hERG and M6PR immunostaining, the time dependence for G601S-hERG to accumulate in the reticula and for the M6PR to redistribute into the puncti was similar. Figure 3B shows that treating cells with podophyllotoxin or vinblastine also caused G601S-hERG and M6PR to accumulate into reticula and puncti, respectively, suggesting that these effects were a consequence of microtubule depolymerization.
In an effort to determine whether the reticula are part of the ER, we performed a series of colocalization experiments with three different antibodies that label the ER, anti-calnexin, anti-KDEL, and anti-Sec-31. Calnexin assists the folding of N-linked glycoprotiens, anti-KDEL recognizes an ER retention signal that is conserved among luminal ER chaperones, and Sec31 labels ER exit sites. Figure 4 shows that in control conditions G601S-hERG primarily colocalized with calnexin and KDEL chaperones. Nocodazole treatment did not alter the immunostaining of calnexin, KDEL chaperones, or Sec31. Nocodazole treatment selectively reduced G601S-hERG colocalization with calnexin, suggesting that the calnexin is excluded from the reticula. Nocodazole did not appear to cause WT-hERG to accumulate in the reticula because WT-hERG colocalization with calnexin did not decrease after nocodazole treatment (supplemental Fig. S3 ). G601S-hERG colocalization with KDEL chaperones was unaffected by nocodazole treatment, and G601S-hERG showed almost no colocalizatoin with Sec31 in control or nocodazole-treated cells. We conclude that microtubule depolymerization caused G601S-hERG to accumulate in reticula that contain KDEL chaperones but not calnexin or Sec31.
We tested whether reticula are part of the ERGIC. An inherent problem with studying protein localization to the ERGIC is that it is difficult to distinguish it from the ER. This is shown in Fig. 5 . HEK293 cells were immunostained for the transitional ER protein Sec16a and the ERGIC marker ERGIC-53. We found that Sec16a and ERGIC-53 showed some overlapping immunostaining. Treating cells in nocodazole caused the ERGIC-53 to fragment into puncti and increased ER-GIC-53 and Sec16a colocalization. This suggests that nocodazole increased ERGIC-53 localization to the ER/transitional ER. Vesicular transport models suggest that antegrade transport between the ER and ERGIC occurs in COPII vesicles, and retrograde transport back to the ER occurs in COPI vesicles (2) . In an attempt to differentiate the ER from the ERGIC, we treated cells in nocodazole and bfa, a fungal metabolite that inhibits COPI vesicular transport. We found that treating cells in nocodazole and bfa caused ERGIC-53 to accumulate in large spherical membranes adjacent to (but not overlapping with) Sec16a. The formation of large spherical ERGIC membranes near the transitional ER likely occurs because proteins are still able to access the ERGIC via COPII transport but are unable to recycle back to the ER in COPI vesicles. Thus treating cells in nocodazole and bfa appears to delineate the ERGIC from the ER. These results are qualitatively similar as those previously reported (18) . Figure 6A shows fluorescent images of cells expressing G601S-hERG immunostained for hERG and ERGIC-53 in control conditions, in cells treated with nocodazole, or in cells treated in nocodazole and bfa. In control conditions there is some colocalization between G601S-hERG and ERGIC-53 immunostaining. Nocodazole increased the colocalization of G601S-hERG and diffuse ERGIC-53 immunostaining in the reticula, but we did not detect overlap between G601S-hERG and the ERGIC-53 puncti (characteristic of the transitional ER). In cells treated with nocodazole and bfa, G601S-hERG still accumulated in the reticula, but the reticula did not colocalize to the spherical ERGIC membranes. The data suggest that G601S-hERG is restricted from the ERGIC. These results are qualitatively similar to those seen with cells expressing the trafficking-deficient LQT2 mutation N470D-hERG but differ from cells expressing WT-hERG (supplemental Fig. S4 ).
These data suggest that G601S-hERG does not traffic to the ERGIC in control conditions. Figure 6B shows G601S-hERG and ERGIC-53 immunostaining in cells treated in E-4031; E-4031 and nocodazole; or E-4031, nocodazole, and bfa. Simply treating cells in E-4031 increased G601S-hERG colocalization with ERGIC-53 compared with control conditions (no drug). In cells treated with E-4031 and nocodazole, G601S-hERG did not accumulate into reticula, and we were able to detect some overlap between G601S-hERG and the ERGIC-53 puncti. Treating cells in E-4031, nocodazole, and bfa also showed that G601S-hERG did not accumulate in the reticula and increased the colocalization of G601S-hERG and ERGIC-53 compared with cells treated in nocodazole and bfa alone. These data suggest that E-4031 allows G601S-hERG to move out of a microtubuledependent QC compartment contiguous with the ER and increases the ER export of G601S-hERG to the ERGIC. G601S-hERG immunostaining and ERGIC-53 colocalization in cells treated with E-4031 were qualitatively similar to cells expressing WT-hERG (supplemental Fig. S4 ). Western blot analyses of cells expressing G601S-hERG in the different treatment conditions showed cells treated in E-4031 or E-4031 and nocodazole increased terminally glycosylated hERG (supplemental Fig. S5 ). Since bfa prevents trafficking to the Golgi, E-4031 treatment did not increase the terminal glycosylation in cells treated with nocodazole and bfa (14) . These data are consistent with E-4031 increasing G601S-hERG trafficking to the Golgi. Previous studies show that the ER retention of the viral tsO45-VSVG-G protein is partially regulated by the ERGIC in cells cultured at nonpermissive temperature (40°C) (2, 15, 24, 25) . We tested whether tsO45-VSV-G colocalized to spherical ERGIC membranes in cells treated with nocodazole and bfa. Figure 7 shows cells coexpressing G601S-hERG and tsO45-VSV-G-GFP cultured at 40°C. G601S-hERG, tsO45-VSV-G-GFP, and ERGIC-53 showed a relatively high degree of colocalization with one another. Cells treated in nocodazole and bfa decreased colocalization between G601S-hERG and ERGIC-53 but increased colocalization between tsO45-VSVG-G-GFP and ERGIC-53. tsO45-VSV-G-GFP clearly colocalized with the ERGIC, whereas G601S-hERG did not. These data demonstrate that tsO45-VSV-G-GFP can access the ERGIC but G601S-hERG cannot. Thus these two proteins are differentially regulated by pre-Golgi QC compartments. The third column shows the overlay. The white arrows in the first column highlight several of the G601S-hERG reticula that form after noc treatment. The scale bars in the third column represent 10 m. The fourth column shows a portion of the overlays (the white dashed box, third column) in more detail, and insets show the overlays in even greater detail (the white dashed box, fourth column). B: corresponding mean Costes' Pearson's coefficient (PC) for the colocalization of G601S-hERG and the different endoplasmic reticulum (ER) markers in control conditions (calnexin, n ϭ 8 fluorescent images, KDEL proteins, n ϭ 10, Sec31, n ϭ 6) or after noc treatment (calnexin, n ϭ 8, KDEL proteins, n ϭ 10, Sec31, n ϭ 8) (*P Ͻ 0.05 compared with control).
DISCUSSION
Previous work studying different N-linked glycoproteins suggest that multiple QC compartments can regulate the trafficking of proteins to the Golgi (2, 17, 26) . For example, unassembled major histocompatibility complex class I molecules are regulated by a perinuclear microtubule-dependent ER QC compartment that is discernable after proteasome inhibition (17, 26) . In addition, several misfolded N-linked glycoproteins partially colocalize to the ERGIC, suggesting that the ERGIC also functions in QC (for review see Ref.
2). We found that the N-linked glycoprotein G601S-hERG, but not tsO45-VSV-G-GFP, was restricted to a microtubuledependent QC compartment in the ER. To our knowledge this is the first study to delineate QC compartments for different N-linked glycoproteins within the same cell. Mezzacasa and Helenius (19) suggest that tsO45-VSV-G-GFP may escape the QC in the ER because overexpression may "overwhelm" ER QC mechanisms. If QC in the ER was overwhelmed by overexpression of tsO45-VSV-G, then it is surprising that G601S-hERG did not "leak" into the ERGIC as well. An alternative possibility is that G601S-hERG and tsO45-VSV-G-GFP may affect the kinetics of protein folding differentially. G601S-hERG may sufficiently slow folding to native-like conformations such that it is readily retained in the ER QC compartment, whereas tsO45-VSV-G may speed fluctuations between misfolded and native-like states, such that transiently folded conformations escape ER QC, but as tsO45-VSV-G misfolds it is recycled back to the ER. The data suggest that the QC compartment in the ER negatively regulates G601S-hERG trafficking to prevent maturation in the Golgi. Further work that delineates the mechanism(s) by which these N-linked glycoproteins are differentially regulated by pre-Golgi QC compartments will be useful in understanding the interplay between protein folding, misfolding, and maturation.
A surprising result is that nocodazole treatment increased the terminal glycosylation of G601S-hERG by Golgi enzymes. The processing of G601S-hERG by Golgi enzymes in nocodazoletreated cells may occur in the ER QC compartment, as the Golgi enzymes recycle though the ER between the Golgi fragments (4, 27, 28) . Regardless, these results clearly demonstrate that an increase in the terminal glycosylation of hERG does not always correlate with an increase in functional expression.
The data suggest that nocodazole treatment affected WThERG and G601S-hERG differently. Nocodazole treatment did not cause WT-hERG to accumulate into reticula, it did not increase the terminal glycosylation of WT-hERG, and it did not decrease WT-hERG colocalization with calnexin. Nocodazole treatment reduced the diffuse intracellular WThERG immunostaining and it increased I hERG . Nocodazole treatment can impact other trafficking pathways, such as endocytosis. Interestingly, nocodazole treatment decreased WT-hERG colocalization with the early endosomal marker EEA1, whereas G601S-hERG showed almost no colocalization with EEA1 in control or nocodazole-treated cells (supplemental Fig. S6 ). Although the employed microscopy techniques do not enable us to determine where a protein has trafficked from, these data suggest nocodazole treatment primarily affected G601S-hERG in the ER and WT-hERG in post-Golgi compartments.
There are several limitations to this work. These results were obtained in a widely used heterologous overexpression system and may differ in cardiac myocytes. Differences in relative expression levels may contribute to these results; however, similar results were seen in multiple cell lines expressing different amounts of G601S-hERG (data not shown) and in cells expressing the trafficking-deficient LQT2 mutation N470D-hERG (supplemental Fig. S4 ). The drugs used in this study can cause cytotoxicity and may have nonspecific effects. Microtubule depolymerizing drugs are currently used as anti-neoplastic agents, but any clinical relevance related to these findings is beyond the scope of this study. Fig. 6 . Representative fluorescent images of cells expressing G601S-hERG immunostained with anti-hERG (red, first column) and ER-GIC-53 (green, second column) in control conditions after being treated in 20 M noc for 2 h, or after being treated in 20 M noc and 10 g/ml bfa for 2 h (noc ϩ bfa) in the absence (A)or the presence (B) of 10 M E-4031. The third column shows the overlay. The white arrows in the first column highlight several of the reticula that form after noc or noc ϩ bfa treatment in the absence of E-4031. The scale bars in the third column represent 10 m. The fourth column shows a portion of the overlays (the white dashed box, third column) in more detail, and insets show the overlays in even greater detail (the white dashed box, fourth column). C: left shows the mean Costes' PC for the colocalization of G601S-hERG and ER-GIC-53 in control cells (n ϭ 12 image), after noc treatment (n ϭ 9), or after treatment in noc ϩ bfa (n ϭ 12) in the absence of E-4031. Right shows the mean Costes' PC for the colocalization of G601S-hERG and ERGIC-53 in control cells (n ϭ 8), after noc treatment (n ϭ 9), or after treatment in noc ϩ bfa in the presence of E-4031 (n ϭ 9) (*P Ͻ 0.05 compared with control; #P Ͻ 0.05 for indicated comparison, and %P Ͻ 0.05 compared with without E-4031). or after treatment in noc ϩ bfa (n ϭ 10). Middle shows the mean Costes' PC for the colocalization of G601S-hERG and ERGIC-53 in control cells (n ϭ 7) or after treatment in noc ϩ bfa (n ϭ 10). Right shows the mean Costes' PC for the colocalization of tsO45-VSV-G-GFP and ERGIC-53 in control cells (n ϭ 7) or after treatment in noc ϩ bfa (n ϭ 10) (*P Ͻ 0.05 compared with control).
In summary, these data are the first to identify that a microtubule-dependent compartment in the ER regulates the retention of a clinically relevant mutation in the absence of proteasome inhibitors. We conclude that identifying mechanisms to prevent the sorting or promote the release of LQT2 mutations from this compartment may represent a novel therapeutic strategy for LQT2.
